Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib adjuvant therapy in high‑risk renal cell carcinoma after nephrectomy
CTR20132932Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sunitinib in renal cell carcinoma (RCC), sponsored by Pfizer. Started Oct 2017; status: completed.
02
Drugs
sunitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on CTR20132932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20132932.